Select Medical Holdings (NYSE:SEM) shares climbed 8% on Tuesday after the company disclosed it has reached a definitive agreement to be acquired by a consortium led by Executive Chairman Robert A. Ortenzio, Senior Executive Vice President Martin F. Jackson and Welsh, Carson, Anderson & Stowe.
Under the terms of the agreement, the consortium will purchase all outstanding Select Medical common shares it does not already own for $16.50 per share in cash, reflecting an enterprise value of $3.9 billion. The cash offer equals an 18% premium relative to the company’s share price on November 24, 2025 - the trading day immediately before a publicly disclosed proposal was submitted - and it represents a 25% premium versus the 90-day volume-weighted average closing price up to that same date. The company’s shares had closed at $15 on Monday.
The Merger Agreement received unanimous approval from the disinterested members of Select Medical’s Board of Directors, following the recommendation of a special committee composed of independent directors. As part of the transaction structure, Mr. Ortenzio, Mr. Jackson and certain affiliates have agreed not to accept cash for their equity holdings; instead, they will roll their equity stakes into the parent entity of the company that will survive the merger. The consortium may extend the opportunity to other members of management and the board to participate in the rollover.
Company documents state the deal is expected to close in mid-2026, subject to customary closing conditions. These include shareholder approval by a majority of the votes cast by holders of shares not owned by the consortium or their affiliates, the expiration of any applicable Hart-Scott-Rodino waiting periods, and receipt of required regulatory approvals. The merger is not conditioned on financing.
Initial rollover participants, who together hold approximately 11.8% of the company’s outstanding shares, have committed to vote in favor of the merger agreement. Following completion of the transaction, Select Medical will become a privately held company and its common shares will be removed from listing on the New York Stock Exchange.
On the research side, Mizuho analyst Ann Hynes maintained an Outperform rating on Select Medical and left a $17.00 price target in place. Hynes commented, "While the acquisition awaits regulatory and shareholder approval, we believe the $16.50 per share valuation is fair, given the volatility in the critical illness and outpatient segments and the underperformance seen in the company’s 2025 results."
The transaction announcement and the board-level approvals detail the framework for taking the company private while preserving a pathway for certain insiders and affiliates to retain economic participation via equity rollover. Market reaction to the proposed deal was immediate in the trading session following the announcement, lifting the shares by 8%.
Deal overview - key points:
- The consortium will pay $16.50 per share in cash for outstanding shares not already owned by the group, valuing the company at an enterprise value of $3.9 billion.
- The offer equals an 18% premium to the November 24, 2025 share price and a 25% premium to the 90-day VWAP ending on that date; shares closed at $15 on the prior trading day.
- The transaction anticipates a mid-2026 close subject to shareholder and regulatory approvals and expiration of Hart-Scott-Rodino waiting periods; it is not subject to a financing condition.
The information above is based on the company's announcement and related statements provided by Select Medical and the named parties to the agreement.